missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human ASB13 (aa 191-267) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (96%), Rat (96%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-66419 (PA5-66419. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
The protein encoded by this gene is a member of the ankyrin repeat and SOCS box-containing family of proteins. They contain ankyrin repeat sequence and a SOCS box domain. The SOCS box serves to couple suppressor of cytokine signalling proteins and their binding partners with the elongin B and C complex, possibly targeting them for degradation. Multiple alternatively spliced transcript variants have been described for this gene, but their full-length sequences are not known.
Specifications
Specifications
| Accession Number | Q8WXK3 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 79754 |
| Name | Human ASB13 (aa 191-267) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 2210015B19Rik; 6430573K02Rik; ankyrin repeat and SOCS box containing 13; ankyrin repeat and SOCS box protein 13; ankyrin repeat and SOCS box-containing 13; ankyrin repeat and SOCS box-containing protein 13; ankyrin repeat domain-containing SOCS box protein 13; ankyrin repeat domain-containing SOCS box protein Asb-13; ASB13; Asb-13; C85285 |
| Common Name | ASB13 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction